Addressing IOP and QOL With LAL, iStent, and Dextenza

Show Description +

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Addressing IOP and QOL With LAL, iStent, and Dextenza

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Please log in to leave a comment.

More in Glaucoma

Treatment Considerations for a Patient With Cataracts and Normal-Tension Glaucoma

John P. Berdahl, MD; Natalia Morales, MD; and Justin Schweitzer, OD, FAAO

Uveitis With Glaucoma

Evripidis Sykakis, MD

The Blind Truth: Too Many Glaucoma Patients Are Lost to Care

J. Morgan Micheletti, MD; and Andrew Williams, MD